---
title: "Zenas BioPharma, Inc. (ZBIO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ZBIO.US.md"
symbol: "ZBIO.US"
name: "Zenas BioPharma, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T04:07:57.534Z"
locales:
  - [en](https://longbridge.com/en/quote/ZBIO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ZBIO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ZBIO.US.md)
---

# Zenas BioPharma, Inc. (ZBIO.US)

## Company Overview

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [zenasbio.com](https://zenasbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: E
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: E (0.80)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 360 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: E

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% |  |
| Net Profit YoY | -161.21% |  |
| P/B Ratio | 3.14 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1054694354.04 |  |
| Revenue | 0.00 |  |

#### Multi Score Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -137.11% | E |
| Profit Margin | 0.00% | D |
| Gross Margin | 0.00% | E |
| Revenue YoY | -100.00% | E |
| Net Profit YoY | -161.21% | E |
| Total Assets YoY | 124.01% | A |
| Net Assets YoY | 18.12% | A |
| Cash Flow Margin | 49.51% | C |
| OCF YoY | -100.00% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 55.08% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Zenas BioPharma, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-161.21%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.14",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1054694354.04",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "0.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-137.11%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-161.21%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "124.01%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "18.12%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "49.51%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "55.08%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.62 | 280/386 | - | - | - |
| PB | 3.31 | 269/386 | 7.12 | 4.79 | 2.31 |
| PS (TTM) | 119.50 | - | 125.60 | 74.72 | 43.79 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 88% |
| Hold | 1 | 13% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 17.84 |
| Highest Target | 55.00 |
| Lowest Target | 22.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ZBIO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ZBIO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ZBIO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ZBIO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**